A phase I, two arm, open-label, randomized, study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in modified release formulations (MR3 and MR4) and compare the bioavailability between MR3, MR4 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Novartis
- 28 Jan 2008 Status change from in progress to completed.
- 08 Feb 2007 New trial record.